NOVEL INTRACELLULAR TARGETS FOR ANTIFUNGAL AGENTS

抗真菌药物的新型细胞内靶点

• 批准号: 2522117
• 负责人: ROBERT S GREENFIELD
• 金额: $ 10万
• 依托单位: SYMBIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-15 至 1999-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2522117
• 关键词: Candida albicans; affinity chromatography; antibiotics; antibody; antifungal agents; antiinfective agents; binding proteins; chemical structure function; chemical synthesis; drug design /synthesis /production; immunocytochemistry; intracellular; laboratory rabbit; metalloporphyrins; molecular cloning; protein binding; protein purification; protein sequence; tissue /cell culture

The aim of this Phase I SBIR study is to identify intracellular binding proteins for novel antifungal agents. Previous studies indicated that our novel antifungal agents bind to specific intracellular sites. We propose to purify the binding proteins by affinity chromatography. Antibodies will be raised against the purified proteins and immunohistochemical studies will be performed on fungi, bacteria and human cells. The binding proteins will be partially sequenced and the sequences will be compared to known proteins in gene data bases. The proteins will also be cloned. The purified binding proteins will serve as novel molecular targets for screening molecular libraries and in analog development. PROPOSED COMMERCIAL APPLICATIONS: Investigations in this study may lead to novel drugs for the treatment of topical and/or systemic fungal infections.

该阶段I SBIR研究的目的是识别细胞内结合 新型抗真菌剂的蛋白质。先前的研究表明我们的 新型抗真菌剂与特定的细胞内部位结合。 我们建议 通过亲和力色谱纯化结合蛋白。 抗体 将针对纯化的蛋白质和免疫组织化学提出 研究将对真菌，细菌和人类细胞进行。结合 蛋白质将部分测序，并将比较序列 在基因数据库中已知的蛋白质。 蛋白质也将被克隆。 纯化的结合蛋白将作为新的分子靶标 筛选分子文库和模拟发展。 拟议的商业应用： 这项研究中的调查可能导致治疗的新药物 局部和/或全身真菌感染。